Sex Differences in Cardiovascular Manifestations
ME/CFS demonstrates a 3:1 to 4:1 female predominance (Jason and Mirin 2018), and emerging evidence suggests that cardiovascular manifestations may differ between sexes beyond simple prevalence differences.
POTS is more common in females, with cohort studies consistently showing 4:1 to 5:1 female-to-male ratios (Hoad et al. 2008). This sex difference exceeds the overall ME/CFS female predominance, suggesting additional sex-specific factors in POTS pathophysiology. Potential contributors include differences in blood volume regulation (females have lower baseline blood volume per kilogram), hormonal effects on vascular tone and autonomic function, and sex differences in autoimmune propensity affecting GPCR autoantibody production.
The NIH deep phenotyping study revealed distinct immune abnormalities in male versus female ME/CFS patients (Walitt et al. 2024), and these differences likely extend to cardiovascular manifestations. Sex hormone effects on endothelial function, baroreflex sensitivity, and autonomic balance may modulate how the underlying disease process manifests cardiovascularly.
Blood volume deficits may be proportionally greater in females. van Campen et al. found that red blood cell mass was reduced in 93.8% of female ME/CFS patients compared to 50% of males, while plasma volume was subnormal in the majority of both sexes Campen, Rowe, and Visser (2018). This sex difference in red cell mass reduction may reflect hormonal influences on erythropoiesis or differential inflammatory effects.
Clinical implications include the need for sex-stratified analysis in cardiovascular research and potentially different therapeutic thresholds. The higher prevalence of POTS in females may warrant lower diagnostic thresholds for autonomic testing referral in female patients with orthostatic symptoms.